Martin H. Voss

Martin H. Voss

Auto-generated profile, based on publicly available information

Martin H. Voss

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 February 2018 in Science
Verified
Journal Article
Closed access
PDF file
DMDiana Miao
Diana Miao
CMClaire A. Margolis
Claire A. Margolis
WGWenhua Gao
Wenhua Gao
MVMartin H. Voss
Martin H. Voss
WLWei Li
Wei Li
EAEliezer Van Allen
Eliezer Van Allen
SNF'ing out antitumor immunity: Immune checkpoint inhibitors induce durable tumor regressions in some, but not all, cancer patients. Understanding the mechanisms that determine tumor sensitivity to these drugs could potentially expand the number of patients who benefit (see the Perspective by Ghorani and Quezada). Pan et al. discovered that tumor cells in which a specific SWI/SNF chromatin remodeling complex had been experimentally inactivated were more sensitive to T cell–mediated killing. The cells were more responsive to interferon-γ, leading to increased secretion of cytokines that promote antitumor immunity. Miao et al. examined the genomic features of tumors from patients with metastatic renal cell carcinoma who had been treated with immune checkpoint inhibitors. Tumors harboring inactivating mutations in PBRM1 , which encodes a subunit of the same SWI/SNF complex, were more likely to respond to the drugs. Science , this issue p. 770 , p. 801 ; see also p. 745

17 November 2016 in Genome Biology
Verified
Journal Article
Open access
PDF file
YŞYasin Şenbabaoğlu
Yasin Şenbabaoğlu
RGRon S. Gejman
Ron S. Gejman
AWAndrew G. Winer
Andrew G. Winer
MLMing Liu
Ming Liu
EAEliezer Van Allen
Eliezer Van Allen
AHAbraham Ari Hakimi
Abraham Ari Hakimi
Tumor-infiltrating immune cells have been linked to prognosis and response to immunotherapy; however, the levels of distinct immune cell subsets and the signals that draw them into a tumor, such as the expression of antigen presenting machinery genes, remain poorly characterized. Here, we employ a gene expression-based computational method to profile the infiltration levels of 24 immune cell populations in 19 cancer types. We compare cancer types using an immune infiltration score and a T cell infiltration score and find that clear cell renal cell carcinoma (ccRCC) is among the highest for both scores. Using immune infiltration profiles as well as transcriptomic and proteomic datasets, we characterize three groups of ccRCC tumors: T cell enriched, heterogeneously infiltrated, and non-infiltrated. We observe that the immunogenicity of ccRCC tumors cannot be explained by mutation load or neo-antigen load, but is highly correlated with MHC class I antigen presenting machinery expression (APM). We explore the prognostic value of distinct T cell subsets and show in two cohorts that Th17 cells and CD8+ T/Treg ratio are associated with improved survival, whereas Th2 cells and Tregs are associated with negative outcomes. Investigation of the association of immune infiltration patterns with the subclonal architecture of tumors shows that both APM and T cell levels are negatively associated with subclone number. Our analysis sheds light on the immune infiltration patterns of 19 human cancers and unravels mRNA signatures with prognostic utility and immunotherapeutic biomarker potential in ccRCC.

3 February 2022 in Cell
Verified
Journal Article
Closed access
BNBastien Nguyen
Bastien Nguyen
CFChristopher Fong
Christopher Fong
ALAnisha Luthra
Anisha Luthra
SSShaleigh A. Smith
Shaleigh A. Smith
RDRenzo G. DiNatale
Renzo G. DiNatale
NSNikolaus Schultz
Nikolaus Schultz

15 April 2021 in Cancer Cell
Verified
Journal Article
Closed access
CKChirag Krishna
Chirag Krishna
RDRenzo G. DiNatale
Renzo G. DiNatale
FKFengshen Kuo
Fengshen Kuo
RSRaghvendra M. Srivastava
Raghvendra M. Srivastava
LVLynda Vuong
Lynda Vuong
AHAbraham Ari Hakimi
Abraham Ari Hakimi

1 October 2019 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
LVLynda Vuong
Lynda Vuong
RKRitesh Kotecha
Ritesh Kotecha
MVMartin H. Voss
Martin H. Voss
AHAbraham Ari Hakimi
Abraham Ari Hakimi
Renal cell carcinoma stands out as one of the most immune-infiltrated tumors in pan-cancer comparisons. Features of the tumor microenvironment heavily affect disease biology and may affect responses to systemic therapy. With evolving frontline options in the metastatic setting, several immune checkpoint blockade regimens have emerged as efficacious, and there is growing interest in characterizing features of tumor biology that can reproducibly prognosticate patients and/or predict the likelihood of their deriving therapeutic benefit. Herein, we review pertinent characteristics of the tumor microenvironment with dedicated attention to candidate prognostic and predictive signatures as well as possible targets for future drug development.Significance: Tumor microenvironment features broadly characterizing angiogenesis and inflammatory signatures have shown striking differences in response to immune checkpoint blockade and antiangiogenic agents. Integration of stromal and immune biomarkers may hence produce predictive and prognostic signatures to guide management with existing regimens as well as future drug development.

1 April 2019 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
AHAbraham Ari Hakimi
Abraham Ari Hakimi
MVMartin H. Voss
Martin H. Voss
FKFengshen Kuo
Fengshen Kuo
ASAlejandro Sanchez
Alejandro Sanchez
MLMing Liu
Ming Liu
RMRobert Motzer
Robert Motzer
Metastasis remains the main reason for renal cell carcinoma (RCC)–associated mortality. Tyrosine kinase inhibitors (TKI) impart clinical benefit for most patients with RCC, but the determinants of response are poorly understood. We report an integrated genomic and transcriptomic analysis of patients with metastatic clear cell RCC (ccRCC) treated with TKI therapy and identify predictors of response. Patients in the COMPARZ phase III trial received first-line sunitinib or pazopanib with comparable efficacy. RNA-based analyses revealed four distinct molecular subgroups associated with response and survival. Characterization of these subgroups identified mutation profiles, angiogenesis, and macrophage infiltration programs to be powerful predictors of outcome with TKI therapy. Notably, predictors differed by the type of TKI received. Our study emphasizes the clinical significance of angiogenesis and immune tumor microenvironment and suggests that the critical effects its various aspects have on TKI efficacy vary by agent. This has broad implications for optimizing precision treatment of RCC. Significance: The determinants of response to TKI therapy in metastatic ccRCC remain unknown. Our study demonstrates that key angiogenic and immune profiles of the tumor microenvironment may affect TKI response. These findings have the potential to inform treatment personalization in patients with RCC. This article is highlighted in the In This Issue feature, p. 453